TZ9

Overview

TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B -induced histone H2A ubiquitination, downregulates intracellular β-catenin , induces G2-M arrest and apoptosis , and inhibits the proliferation and migration of metastatic human breast cancer cells.

Application

Products | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > E1/E2/E3 Enzyme | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-18643
• CAS No.: 1002789-86-7
• Molecular Formula: C17H14N6O4
• Molecular Weight: 366.33
• Purity: 99.27%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.82 mM); Clear solution
• Availability: In-stock

Source

Original product source